Jiang Hai

Biography

JIANG Hai is a Professor of Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, hanghai, China. Research Interests: Improving the efficacy of anti-cancer therapy is a major challenge for healthcare and biomedical research. With the rapidly improving understanding of human cancer genome, significant opportunities lie in the rational design of personalized medicine that attacks specific weakness of individual cancer. In addition, advances in chemistry and screening technology also allow for the development of new and more effective anti-cancer drugs. Combining RNAi technology and mouse models of cancer, we plan to address these important questions, aiming at establishing principles and tools for improving cancer therapy. Major research topics in my lab include: 1) Modeling recurrent cancer genotypes to explore the genotype-specific vulnerabilities of human cancer 2) Screening and development of new anti-cancer drugs using a functional genetic drug-characterization approach 3) Knowledge-based redesign and improvement of existing anti-cancer drugs

Research Interest

Improving the efficacy of anti-cancer therapy is a major challenge for healthcare and biomedical research. With the rapidly improving understanding of human cancer genome, significant opportunities lie in the rational design of personalized medicine that attacks specific weakness of individual cancer. In addition, advances in chemistry and screening technology also allow for the development of new and more effective anti-cancer drugs. Combining RNAi technology and mouse models of cancer, we plan to address these important questions, aiming at establishing principles and tools for improving cancer therapy. Major research topics in my lab include: 1) Modeling recurrent cancer genotypes to explore the genotype-specific vulnerabilities of human cancer 2) Screening and development of new anti-cancer drugs using a functional genetic drug-characterization approach 3) Knowledge-based redesign and improvement of existing anti-cancer drugs